Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Adjuvant sequential chemotherapy plus radiotherapy for LABC after radical cystectomy: Urothelial carcinoma subgroup analysis

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.02.19
Views: 798

Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA

Prof Brian Baumann speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about a randomised phase III clinical trial comparing adjuvant sequential chemotherapy plus radiotherapy versus adjuvant radiotherapy alone for locally advanced bladder cancer (LABC) after radical cystectomy.

He explains that a sub group analysis was presented looking at the 53% of patients with urothelial carcinoma, the most common histology in Europe and North America, to see if adjuvant chemotherapy had a benefit in that population.

Prof Baumann reports that the addition of adjuvant chemotherapy significantly improved disease free survival with a difference of 62% at 2 years to 48% at 2 years for radiotherapy alone.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation